Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s

Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity

(2016) Faidon Magkos et al.   Cell Metabolism

Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline

(2015) Caroline M. Apovian et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010

(2015) Ying Xia et al.   Obesity

AACE Comprehensive Diabetes Management Algorithm 2013

(2015) Alan Garber et al.   Endocrine Practice

Prevalence of Childhood and Adult Obesity in the United States, 2011-2012

(2014) Cynthia L. Ogden et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Safety and Efficacy of Lorcaserin: A Combined Analysis of the BLOOM and BLOSSOM Trials

(2014) Louis Aronne et al.   POSTGRADUATE MEDICINE

Clinical Practice Guidelines for Healthy Eating for the Prevention and Treatment of Metabolic and Endocrine Diseases in Adults: Cosponsored by The American Association of Clinical Endocrinologists/The American College of Endocrinology and The Obesity Society

(2013) J. Gonzalez-Campoy et al.   Endocrine Practice

Time series analyses of the effect of FDA communications on use of prescription weight loss medications

(2013) Jason P. Block et al.   Obesity

Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults

(2013) Louis J. Aronne et al.   Obesity

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

(2013) Caroline M. Apovian et al.   Obesity

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial

(2013) Michael Roden et al.   Lancet Diabetes & Endocrinology

Successful Weight Loss Among Obese U.S. Adults

(2012) Jacinda M. Nicklas et al.   AMERICAN JOURNAL OF PREVENTIVE MEDICINE

Management of Obesity in the National Health and Nutrition Examination Survey (NHANES), 2007–2008

(2012) Nithushi R. Samaranayake et al.   ANNALS OF EPIDEMIOLOGY

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

(2012) K. Stenlöf et al.   DIABETES OBESITY & METABOLISM

Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study

(2012) Patrick M. O'Neil et al.   Obesity

Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study

(2011) W Timothy Garvey et al.   AMERICAN JOURNAL OF CLINICAL NUTRITION

Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes

(2011) R. R. Wing et al.   DIABETES CARE

Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial

(2011) Kishore M Gadde et al.   LANCET

Tackling Obesity

(2010) Robert F. Kushner   ARCHIVES OF INTERNAL MEDICINE

Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

(2010) E. Ferrannini et al.   DIABETES CARE

How Physician Obesity Specialists Use Drugs to Treat Obesity

(2009) Ed J. Hendricks et al.   Obesity